Bicalutamide Does Not Raise Transaminases Compared to Alternative Anti-Androgen Regimens Among Transfeminine Adolescents and Young Adults: A Retrospective Cohort Study

    February 2024
    Katie Burgener, Brian J. DeBosch, Jinli Wang … Cynthia Herrick
    Studysummary In this study, bicalutamide at low doses was not linked to significant liver enzyme changes compared to other androgen-blocking treatments in transfeminine adolescents and young adults, suggesting its safety with careful monitoring for this population over one year.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on medrxiv.org →
    Discuss this study in the Community →

    Research cited in this study 5

    1. The Utility of Monitoring Potassium in Transgender, Gender Diverse, and Nonbinary Individuals on Spironolactone Journal of the Endocrine Society · 2022
    2. Safety of Oral Bicalutamide in Female Pattern Hair Loss: A Retrospective Review of 316 Patients Journal of The American Academy of Dermatology · 2020
    3. Combined Oral Contraception and Bicalutamide in Polycystic Ovary Syndrome and Severe Hirsutism: A Double-Blind Randomized Controlled Trial The Journal of Clinical Endocrinology & Metabolism · 2017
    4. Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline The Journal of Clinical Endocrinology & Metabolism · 2017
    5. Hepatotoxicity with Low- and Ultralow-Dose Flutamide: A Surveillance Study on 203 Hyperandrogenic Young Females Fertility and Sterility · 2012